Disease response and treatment status timelines for deep responders. Patients who received continuous venetoclax (n = 14) (A) or limited-duration venetoclax (n = 19) (B). In each panel, patients are grouped by their best iwCLL response category. In panel B, the 4 patients receiving retreatment with venetoclax or venetoclax plus rituximab after progression are grouped together for ease of reference. ^aThe first patient received a second course of rituximab and increased dose of venetoclax to 600 mg/day upon progression, and then achieved CR with uMRD. ^bPatient was retreated with rituximab for thrombocytopenia unrelated to CLL progression; the patient withdrew because of myelodysplasia 6 months after data cutoff for the publication. ^cThe patient proceeded to elective allograft in CR. ^dPD assessment data were not included in the clinical database at the time of the data cutoff. nPR, nodular PR; PD, progressive disease; Ven, venetoclax.